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How does HPV vaccination status relate to
risk perceptions and intention to
participate in cervical screening? a survey
study
Mie Sara Hestbech1*, Dorte Gyrd-Hansen2, Jakob Kragstrup1, Volkert Siersma1 and John Brodersen1,3
Abstract
Background: Women in several countries will soon be covered by two preventive programmes targeting cervical
cancer: HPV vaccination and cervical screening. The HPV vaccines are expected to prevent approximately 70 % of
cervical cancers. It has been speculated, that HPV vaccinated women will not attend screening because they falsely
think that the vaccine has eliminated their cervical cancer risk. The aim of this study was to investigate the
association between HPV vaccination status and perceptions of cervical cancer risk; perceptions of vaccine effect;
and intention to participate in cervical screening. Furthermore, to investigate associations between perceptions of
cervical cancer risk and intention to participate in cervical screening.
Methods: A random sample of Danish women from the birth cohorts 1993–1995 was invited to complete a
web-based questionnaire concerning risk perceptions and intentions to participate in cervical screening. Main
outcomes were: perceived lifetime-risk of cervical cancer; perceived HPV vaccine effect; and intention to participate
in cervical screening.
Results: HPV vaccinated women more often than unvaccinated women intended to participate in screening:
adjusted odds ratio (OR) for being HPV vaccinated when intending to participate in screening of 3.89 (95 % CI: 2.
50–6.06). HPV vaccinated women perceived cervical cancer risk to be higher than unvaccinated women did:
adjusted OR of 0.11 (95 % CI: 0.03–0.39) and 0.51 (95 % CI: 0.33–0.78) for being HPV vaccinated while having the
lowest perception of risk (in two different pre-specified dichotomisations). HPV vaccinated women perceived the
vaccine effect to be larger than unvaccinated women did: adjusted OR of 0.31 (95 % CI: 0.18–0.51) and 0.37
(95 % CI: 0.25–0.53) for being HPV vaccinated while having the lowest perception of vaccine effect (in two different
pre-specified dichotomisations). There were no associations between perceived cervical cancer risk and intention to
participate in screening.
Conclusions: HPV vaccinated women more often than unvaccinated women intended to participate in screening
and they perceived cervical cancer risk to be higher and the vaccine effect to be larger than unvaccinated women
did. However, in our analyses, risk perceptions could not explain screening intentions neither among vaccinated nor
among unvaccinated women.
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Background
Women in several countries will soon be covered by two
preventive programmes targeting cervical cancer: HPV
vaccination and cervical screening. Screening for cervical
cancer has been followed by a reduction in cervical can-
cer incidence and mortality assumedly caused by screen-
ing [1]. The two HPV vaccines currently on the market
prevent infection with HPV types 16 and 18, which are
responsible for approximately 70 % of cervical cancers
[2]. Thus, a significant reduction in cervical cancer inci-
dence is expected among the women vaccinated before
sexual debut. The first women vaccinated as adolescents
have recently entered the cervical screening programme,
and some countries have revised their screening pro-
grammes [3, 4].
Women’s knowledge about cervical cancer is generally
poor, and they overestimate their risk of cervical cancer
and the effect of cervical screening [5–7]. After
implementation of the vaccine, women’s knowledge and
attitudes to cervical screening have been investigated
[8–13]. The concern has been raised, that the HPV vac-
cine gives “a false sense of security” because women be-
lieve that they have eliminated their risk of cervical
cancer [11, 14]. However, these studies were conducted
a considerable time before the study populations were
invited for screening. A few studies have investigated ac-
tual screening behaviour among the first women vacci-
nated in catch-up programmes: An Australian study
suggests that vaccinated women are being screened at
lower rates than unvaccinated women [15], while a study
from the UK indicates the opposite [16]. However, we
still do not know how screening behaviour will be
among women vaccinated as adolescents.
Therefore, our aim was to investigate if there was an as-
sociation between HPV vaccination status and perceptions
of cervical cancer risk; perceptions of vaccine effect; and
intention to participate in cervical screening. Furthermore,
we investigated associations between risk perceptions and
intention to participate in cervical screening.
Methods
Setting
This study was carried out in Denmark. The Danish
Health Authority recommends cytology screening trien-
nially for women aged 23–49 years, and every 5 years in
the age group 50–64 [17]. Screening samples are taken
by GPs. From 1 October 2008, women born 1993–1995
were offered free HPV vaccination in a catch-up
programme, and from 1 January 2009, free vaccination
was offered to all girls turning 12 years as a part of the
national childhood immunisation programme. Approxi-
mately, 80 % of these birth cohorts have received all
doses of the vaccine [18], and will enter the cervical
screening programme from 2016 and onwards.
Population and procedure
The study population was females from the birth cohorts
1993, 1994 and 1995. A random sample of these cohorts
was drawn using the public register Statistics Denmark.
We received personal contact information drawn from
public registers. Telephone numbers were matched on
names and address. Those who did not have an obtain-
able publicly registered telephone number were ex-
cluded. The remaining potential respondents were sent
an SMS (short text message) containing a link to the
survey. No gifts, prices or other incentives were used.
Data collection started 8 April 2015. Reminders were
sent 8 days and 14 days after data collection started. The
data collection ended 20 May 2015, when no further re-
sponses had been received for more than two weeks.
Survey data were supplemented with socio-demographic
data obtained from Statistics Denmark. The Danish Civil
Registration System (CRS) contains information on all
individuals with a permanent address in Denmark [19].
Each individual receives a unique personal identification
number (CPR-number). CPR-numbers were used to link
each potential respondent to data from registers in
Statistics Denmark. Anonymity was assured by automatic-
ally generated ID-numbers replacing CPR-numbers in the
analysis database.
We included the following socio-demographic register-
based variables: Ethnicity, degree of urbanisation, com-
pleted educational level, parents’ educational level, and
primary care contacts within the previous year (a measure
of use of healthcare services). In order to obtain current
information on the women’s educational level, we asked
respondents about their on-going education in the
questionnaire.
Questionnaire
A web-based questionnaire, compatible with smart-
phones and tablets, was developed with the programme
Survey Xact.
In the first part of the questionnaire, respondents were
asked about their educational level and HPV vaccination
status. Subsequently, they were asked about their
perception of lifetime-risk of cervical cancer for an HPV
unvaccinated woman and successively for an HPV
vaccinated woman. In the second part of the question-
naire all potential respondents were randomised to one of
four study arms receiving four different information mod-
ules, respectively. Finally, all respondents were asked
about their intention to participate in cervical screening.
The questionnaire did not allow respondents to go back
and change their responses to previous questions, thus the
questions concerning risk perceptions were not affected
by the information modules later in the questionnaire.
The results from the randomised trial of the effect of
the information modules will be reported elsewhere [20].
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In the present study, we focused on data concerning vac-
cination status and risk perception collected prior to
randomisation to the information modules, and on
intention to participate in screening assessed after the
information modules. We used data from all four study
arms. There were no statistically significant socio-
demographic differences between study arms [20].
The first draft of questionnaire items was made
through an iterative process involving consecutive dis-
cussions among all authors. The final version was gener-
ated via qualitative interviews with 12 women in the
target group. A combination of two techniques was ap-
plied: Think-aloud interviewing and cognitive probing
[21, 22], ensuring functionality, understandability and
content validity (ad-hoc translated version of the ques-
tionnaire is available as Additional file 1).
Outcomes
We used four self-reported outcomes: Perceived lifetime-
risk of cervical cancer conditional on negative HPV vac-
cination status; perceived lifetime-risk of cervical cancer
conditional on positive HPV vaccination status; perceived
HPV vaccine effect; and intention to participate in cervical
screening.
We asked respondents to report their perceptions of i)
lifetime-risk of cervical cancer for an HPV unvaccinated
woman (unvaccinated cervical cancer risk) and ii)
lifetime-risk of cervical cancer for an HPV vaccinated
woman (vaccinated cervical cancer risk). Respondents
were to provide their answer in terms of number of
women per 1000 women that will develop cervical can-
cer before the age of 75. The answer was to be given on
a slider ranging from zero to 1000.
In our subsequent analyses, we calculated each re-
spondent’s perception of the risk reduction in percentage
attained by the HPV vaccine by dividing their estimate
of vaccinated cervical cancer risk with their estimate of
unvaccinated cervical cancer risk multiplied with 100.
Thus, we did not ask respondents directly about their
perception of the vaccine effect. The rationale was to
make the questionnaire as short and as easy to under-
stand as possible. Furthermore, we wanted an intuitive
answer; we did not expect the majority of the respon-
dents to have the exact answer to this question.
In our analyses of association between risk perceptions
and intention to participate in screening, we matched
vaccination status with the relevant perceived cervical
cancer risk.
The distributions of the risk perception outcomes dif-
fered between HPV vaccinated and unvaccinated respon-
dents (Figs. 2, 3 and 4). For both groups distributions
were non-normal with extreme outliers. Therefore, for
robust analyses that were not dependent on the com-
parison of means or other measures of centrality, we
used logistic regression on dichotomised versions of the
risk perception outcomes defined by different cut-off
values. Perceived cervical cancer risk was dichotomised
by three cut-offs: <11 per 1000 vs. ≥11 per 1000; <101
per 1000 vs. ≥101 per 1000; and <501 per 1000 vs. ≥501
per 1000. The first cut-off was based on the actual
lifetime-risk in Denmark, which is 9 cervical cancer
cases per 1000 women [23]. The two other cut-offs (101
and 501) were based on the graphical distribution of
responses, dividing responses in groups that matched
the range of the responses (cut-offs are marked in
Figs. 2 and 3).
Fig. 1 Flow-diagram of participants
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Perceived HPV vaccination effect was likewise dichoto-
mised by three cut-offs: ≤0 % vs. >0 %; <60 % vs. ≥60 %;
and <95 % vs. ≥95 %. The first cut-off grouped the cases
where respondents reported a higher risk for a vaccinated
woman than for an unvaccinated woman, producing a
negative vaccination effect (indicating miscomprehen-
sion). The second cut-off was set at the lower limit of an
approximately correct estimate of the expected vaccine ef-
ficacy which is approximately 70 % [2]. The third cut-off
grouped those respondents who perceived the vaccine ef-
fect to be nearly complete (cut-offs are marked in Fig. 4).
Intention to participate in cervical screening is an ac-
cepted outcome measure, previously used in the context
of cervical screening [24]. The question “Do you think
that you will attend cervical screening?” had three re-
sponse categories: “Yes”, “no” and “I do not know”. We
dichotomised the outcome by merging “no” and “I do
not know”.
Statistical analyses
Analyses of the relations between (i) HPV vaccination
status and intention to participate in screening (ii) HPV
vaccination status and risk perceptions and (iii) risk per-
ceptions and intention to participate in screening were
conducted applying logistic regression analysis. We con-
ducted the unadjusted analyses as well as adjusted for
the following socio-demographic variables: Year of birth,
ethnicity, degree of urbanisation, completed educational
Table 1 Baseline characteristics and drop-out analyses
Respondents Non-respondents Telephone number
unavailablea
Total p-value Total n in each group
included in analysis
n (%) n (%) n (%) n (%) (n/n/n)
Total n in population 977 2305 1173 4455
Year of birth 977/2305/1173
1993 349 (40.58) 658 (28.55) 349 (35.72) 1483 (33.29)
1994 320 (31.97) 788 (34.19) 320 (32.75) 1483 (33.29)
1995 308 (27.45) 859 (37.27) 308 (31.53) 1489 (22.42) <0.0001
Etnicity 954/2249/1078
Danish 879 (92.14) 1974 (87.77) 924 (85.71) 3777 (88.23)
Other 75 (7.86) 275 (12.23) 154 (14.29) 504 (11.77) <0.0001
Urbanisation 977/2305/1173
Dense 224 (22.93) 370 (16.05) 290 (24.72) 884 (19.84)
Intermediate 102 (10.44) 282 (12.23) 144 (12.28) 528 (11.85)
Thinly pop. 651 (66.63) 1653 (71.71) 739 (63.00) 3043 (68.31) <0.0001
Educational level (completed)b 931/2196/1036
I + II + III + IV 359 (38.56) 633 (28.76) 432 (41.70) 1424 (34.17)
V 572 (61.44) 1563 (71.24) 604 (58.30) 2739 (65.83) <0.0001
Parents educational levelbd 930/2173/1022
I 37 (3.98) 88 (4.05) 31 (3.03) 156 (3.78)
II 118 (12.69) 230 (10.58) 114 (11.15) 462 (11.20)
III 35 (3.76) 79 (3.64) 38 (3.72) 152 (3.68)
IV 477 (51.29) 1044 (48.04) 455 (44.52) 1976 (47.90)
V 263 (28.28) 732 (33.69) 384 (37.57) 4125 (33.43) 0.0050
Number of primary care contacts
in the previous yearc
977/2305/1173
0 83 (8.50) 228 (9.89) 204 (17.39) 515 (11.56)
1–10 497 (50.87) 1133 (49.15) 508 (43.31) 2138 (47.99)
11–20 221 (22.62) 532 (23.08) 255 (21.74) 1008 (22.63)
>20 176 (18.01) 412 (17.87) 206 (17.56) 794 (17.82) <0.0001
a Including 11 responders that were outside target group
b Classified according to highest completed (or on-going) level of education: 1: Second stage of tertiary education, 2: First stage of tertiary education, bachelors
and equivalent, 3: Post-secondary non-tertiary education, 4: Secondary education, 5: Primary education
c Personal contacts for all purposes, telephone- and e-mail contacts
dThe highest level of mother or father
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level, self-reported on-going educational level, parents’
educational level, and primary care contacts within the
previous year. Moreover, we adjusted for study arm in-
cluding interaction between study arm and HPV vaccin-
ation status (thereby controlling for the information
provided in the randomised trial previously described).
All calculations were made in SAS v9.4.
Results
Participant flow and recruitment
In the random sample of 4455 women, 3293 (73.9 %)
had a publicly registered telephone number. The overall
response rate was 30.0 % (n = 988) with 25 % (n = 823)
completing all parts of the questionnaire. We received
26 e-mails from potential respondents, who had received
Table 2 Baseline characteristics by vaccination status
HPV vaccinated
respondents
Non-vaccinated
respondents
Total p-value Total n in each group
included in analysis
n (%) n (%) N (%) (n/n)
Total n in population 698 251 949
Year of birth 698/251
1993 270 (38.68) 69 (27.49) 339 (35.72)
1994 236 (33.81) 78 (31.08) 314 (33.09)
1995 192 (27.51) 104 (41.43) 296 (31.19) 0.0001
Etnicity 682/244
Danish 641 (93.99) 212 (86.89) 853 (92.12)
Other 41 (6.01) 32 (13.11) 73 (7.88) 0.0004
Urbanisation 698/251
Dense 174 (24.93) 43 (17.13) 217 (22.87)
Intermediate 77 (11.03) 21 (8.37) 98 (10.33)
Thinly pop. 447 (64.04) 187 (74.50) 634 (66.81) 0.0100
Educational level (completed)a 669/236
I + II + III + IV 288 (43.05) 64 (27.12) 352 (38.90)
V 381 (56.95) 172 (72.88) 553 (61.10) <0.0001
Self-reported educational level (on-going)a 698/251
I 126 (10.05) 25 (9.96) 151 (15.91)
II 109 (15.62) 49 (19.52) 158 (16.65)
III 37 (5.30) 8 (3.19) 444 (46.79)
IV 366 (52.44) 78 (31.08) 114 (12.01)
V 38 (5.44) 76 (30.28) 37 (3.90)
Unknown 22 (3.15) 15 (5.98) 37 (3.90) <0.0001
Parents educational levelac 676/228
I 28 (4.14) 8 (3.51) 36 (3.98)
II 83 (12.28) 30 (13.16) 113 (12.50)
III 24 (3.55) 11 (4.82) 35 (3.87)
IV 358 (52.96) 106 (46.49) 464 (51.33)
V 183 (27.07) 73 (32.02) 256 (28.32) 0.4260
Number of primary care contacts in the previous yearb 698/251
0 54 (7.74) 26 (10.36) 80 (8.43)
1–10 358 (51.29) 127 (50.60) 485 (51.11)
11–20 159 (22.78) 56 (22.31) 215 (22.66)
>20 127 (18.19) 42 (16.73) 169 (17.81) 0.6231
a Classified according to highest completed (or on-going) level of education: I: Second stage of tertiary education, II: First stage of tertiary education, bachelors
and equivalent, III: Post-secondary non-tertiary education, IV: Secondary education, V: Primary education
b Personal contacts for all purposes, telephone- and e-mail contacts
cThe highest level of mother or father
Hestbech et al. BMC Public Health  (2016) 16:708 Page 5 of 11
an SMS but were not in the target group (males, older
age group). Eleven of these 26 persons had responded to
the questionnaire and their responses were excluded
from the analyses. Of the remaining 977, 949 (28.8 %)
completed the question concerning HPV vaccination
status and were included in the analyses (Fig. 1).
Socio-demographic characteristics and drop-out analyses
Socio-demographic characteristics of the total study
sample are listed in Table 1. Drop-out analyses revealed
differences between women with no available telephone
number, non-respondents and respondents on all in-
cluded variables. Relative to non-respondents, respon-
dents were more frequently ethnic Danes and more
likely to have more than primary education (+9 years of
schooling), as were their parents. They also more often
lived in a densely populated area and had more primary-
care contacts in the previous year.
Socio-demographic characteristics of HPV vaccinated
respondents versus unvaccinated respondents are listed
in Table 2. Statistically significant differences were found
between these two groups: HPV vaccinated respondents
were more frequently of Danish ethnicity and more
often living in a densely populated area than unvaccin-
ated. Women with only primary education were over-
represented among the unvaccinated.
Main results
Distributions of i) unvaccinated cervical cancer risk, ii)
vaccinated cervical cancer risk, iii) the implied HPV vac-
cine effect are shown in Figs. 2, 3 and 4. The median
perceived unvaccinated cervical cancer risk was 261 per
1000 (282 per 1000 among HPV vaccinated respondents,
242 per 1000 among unvaccinated respondents) (Fig. 2).
The median perceived vaccinated cervical cancer risk
was 68 per 1000 (59 per 1000 among HPV vaccinated
respondents, 77 per 1000 among unvaccinated respon-
dents) (Fig. 3). Thus, the median perceived HPV vaccine
effect was 74.6 % (77.1 % among HPV vaccinated re-
spondents, 58.9 % among unvaccinated respondents)
(Fig. 4). The proportion of HPV vaccinated women who
intended to participate in screening was 87.1 and 72.5 %
of the unvaccinated women. The adjusted odds ratio
(OR) for being HPV vaccinated when intending to
Fig. 2 Unvaccinated cervical cancer risk (number of HPV unvaccinated women per 1000 who will develop cervical cancer before the age of 75)
as assessed by HPV vaccinated and unvaccinated respondents (x-axis: assessed risk, y-axis: number of respondents) (Green line: median. Dotted red
lines: cut-offs used in analyses)
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participate in screening was 3.89 (95 % CI: 2.50–6.06)
(Table 3).
We found that HPV vaccinated women perceived cer-
vical cancer risk to be higher than unvaccinated women
did. The association between respondents’ own HPV
vaccination status and perceptions of unvaccinated
cervical cancer risk was statistically significant in the two
pre-specified dichotomisations with the lowest cut-offs.
(Adjusted OR of 0.11 (95 % CI: 0.03–0.39) for being vac-
cinated while being in the lowest risk perception group
when cut-off was set at <11 per 1000 women; adjusted
OR of 0.51 (95 % CI: 0.33–0.78) for being vaccinated
while being in the lowest risk perception group when
cut-off was set at <101 per 1000 women) (Table 3).
We found that HPV vaccinated women perceived the
vaccine effect to be larger than unvaccinated women
did. The association between respondents’ HPV vaccin-
ation status and perceived vaccine effect was statistically
significant in the two pre-specified dichotomisations
with the lowest cut-offs. (Adjusted OR of 0.31 (95 % CI:
0.18–0.51) for being vaccinated while being in the lowest
group when cut-off was set at <0 %; adjusted OR of 0.37
(95 % CI: 0.25–0.53) for being vaccinated while being in
the lowest group when cut-off was set at <60 %)
(Table 3).
Finally, we found that there were no significant associa-
tions between perceived cervical cancer risk subject to
HPV vaccination status and intention to participate in
screening for none (with one exception) of the pre-
specified dichotomisations (see Additional file 2: Table S1).
To test whether the association could have been influ-
enced by the information modules, we tested the
addition of an interaction between study arm and per-
ceived cervical cancer risk on the outcome intention to
participate in screening in the models. None of these
interactions were found significant.
Discussion
HPV vaccinated women more often than unvaccinated
women intended to participate in screening and they
perceived cervical cancer risk to be higher and the vac-
cine effect to be larger than unvaccinated women did.
However, in our analyses, risk perceptions could not
Fig. 3 Vaccinated cervical cancer risk (number of HPV vaccinated women per 1000 who will develop cervical cancer before the age of 75) as
assessed by HPV vaccinated and unvaccinated respondents (x-axis: assessed risk, y-axis: number of respondents) (Green line: median. Dotted red
lines: cut-offs used in analyses)
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explain screening intentions among neither vaccinated
nor unvaccinated women.
The response rate of 29.7 % is low, but the age group
might be considered a “hard-to-reach” group in the context
of survey research. Drop-out analyses reveal socio-
demographic participation bias: respondents seem to come
from better educated families. Completing the questionnaire
would potentially have been more cognitively challenging
for the non-respondents, which might have created in-
creased random error due to incomplete understanding of
the questionnaire. We, however, have no reason to believe
that our results are highly sensitive to this response bias.
Some respondents implicitly reported a negative effect
of the HPV vaccine. We assume that these results are
due to misinterpretations of the questions. Since our
measure of respondents’ perceptions of the effect of
HPV vaccination are derived indirectly from the former
two questions on cervical cancer risk subject to HPV
status, any misinterpretations of these two questions will
spill over onto the perceived HPV effect. The bias intro-
duced by such random errors was reduced by dichoto-
mising risk-perception outcomes.
One may question web-based survey methods and our
use of smartphones via an SMS-link as administration
form. However, several studies have found that the valid-
ity of web-based methods of administration are equal to
paper questionnaires [25, 26]. Moreover, studies have
shown that the use of PDA, which is highly comparable
to a modern smartphone, as administration method is
not inferior to other more commonly used methods in
survey research [27, 28]. Since the target group of this
survey was young women who are generally very familiar
with the use of smartphones [29], we believe that our
method of administration is a strength of this study. Fur-
thermore, the use of personal telephones potentially in-
creased the likelihood that the intended individual
answered the survey. The electronic format does, how-
ever, introduce a potential source of bias: Respondents
were to provide their answer to the risk perception ques-
tions on a slider ranging from 0 to 1000 with the slider
set at the default position 500. This might have caused
some women to place the slider near the default pos-
ition. Although we thought to minimise this problem by
designing the questionnaire such that one could not
Fig. 4 Implied HPV vaccine effect (%) (relative risk difference between unvaccinated cervical cancer risk and vaccinated cervical cancer risk) as
assessed by HPV vaccinated and unvaccinated respondents (x-axis: assessed risk difference, y-axis: number of respondents) (Green line: median.
Dotted red lines: cut-offs used in analyses)
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proceed without moving the slider, we still observe a
“hump” around 500 for the question concerning cancer
risk conditional on negative HPV vaccination status
(Fig. 2). Since the use of a slider is a relatively new
method in survey research, there are, to our knowledge,
no studies validating an electronic slider. However, the
slider is comparable to a VAS scale, and the hump we
observe could also be caused by central tendency bias,
which is known from scales in general.
A strength of this study is that we were able to control
for a number of potential confounders by adjusting for a
number of socio-demographic variables obtained from
registers and questionnaire data.
Our study confirms previously observed socio-
demographic inequalities between HPV vaccinated and
unvaccinated women [16, 30–32]. The proportion of
women intending to participate in screening in our study
is a little higher than current screening rates in Denmark
among vaccinated as well as unvaccinated women [33].
Overall, respondents, HPV vaccinated as well as unvac-
cinated, had highly inflated perceptions of cervical can-
cer risk. Such overestimations have been observed
previously in other survey studies conducted before and
after implementation of the HPV vaccine [5, 9]. How-
ever, HPV vaccinated women perceived the risk condi-
tional on negative HPV vaccination status as higher and
the risk conditional on positive HPV vaccination status
as lower than unvaccinated women did. In other words,
HPV vaccinated women perceived the vaccine to be
more effective than did unvaccinated women. This could
possibly be explained by the classic theory of cognitive
dissonance [34]: women who are unvaccinated might
unconsciously evaluate the HPV vaccine less favourably
to resolve any dissonance between their perception of
the vaccine and their own vaccination status.
Risk perceptions should expectedly be a predictor of
screening intentions. However, we were not able to dem-
onstrate such a relation in this study. This could be due
to lack of power, since there was a tendency towards
women (vaccinated as well as unvaccinated) with lower
perception of cervical cancer risk to be less inclined to
participate in screening.
We found a strong association between HPV vaccin-
ation status and intention to participate in screening
with more HPV vaccinated women than unvaccinated
women intending to participate, even after adjusting for
a number of socio-demographic variables. This is in line
with the findings from a previous survey of Scottish
school girls [35] and a cohort study from the UK [16].
Our results suggest that we should not expect that vacci-
nated women will not attend screening due to a false as-
sumption that they are completely protected against
cervical cancer. This is also supported by a median per-
ceived HPV vaccine effect of 77.1 % among HPV vacci-
nated women, indicating an overall realistic perception
of the vaccine effect. That unvaccinated women might
choose not to attend cervical screening can, however,
raise concern. Socio-demographic inequality is well-
known in screening programmes [36–41]. A previous
study has specifically shown that non-attenders in the
Danish cervical screening programme have less
favourable socio-demographic profiles than attenders,
e.g. shorter education and limited use of primary
health care [42]. If non-attenders are also less likely
Table 3 HPV vaccination status as predictor of screening intention and risk perceptions
Outcome Total n included
in analysis
(unadjus-ted/adjusted)
n(%) HPV vaccinated
with outcome
(unadjusted/adjusted)
n(%) non-vaccinated
with outcome
(unadjusted/adjusted)
OR (unadjusted)
for being HPV
vaccinated (95 % CI)
p-value
(unadjusted)
OR (adjusted)a
for being HPV
vaccinated (95 % CI)
p-value
(adjusted)
Screening intention
Yes vs. no/do
not know
835/783 562 (87.1)/535 (87.0) 119 (62.6)/105 (62.5) 4.04 (2.78–5.87) <0.0001 3.89 (2.50–6.06) <0.0001
Perceived cervical cancer riskb
<11 per
1000 women
910/856 5 (0.7)/5 (0.8) 12 (5.4)/11 (5.5) 0.13 (0.05–0.37) 0.0001 0.11 (0.03–0.39) 0.0005
<101 per
1000 women
910/856 103 (15.0)/98 (14.9) 64 (28.6)/55 (27.5) 0.44 (0.31–0.63) <0.0001 0.51 (0.33–0.78) 0.0019
<501 per
1000 women
910/856 523 (76.2)/500 (76.2) 177 (79.0)/158 (79.0) 0.85 (0.59–1.23) 0.3917 0.71 (0.46–1.09) 0.1207
Perceived HPV vaccine effect
<0 % 904/851 43 (6.3)/43 (6.6) 53 (24.3)/44 (22.6) 0.21 (0.13–0.32) <0.0001 0.31 (0.18–0.51) <0.0001
<60 % 904/851 179 (24.8)/163 (24.9) 109 (50.0)/96 (49.2) 0.33 (0.24–0.45) <0.0001 0.37 (0.25–0.53) <0.0001
<95 % 904/851 569 (82.9)/542 (82.6) 191 (87.6)/173 (88.7) 0.69 (0.44–1.08) 0.1024 0.67 (0.39–1.13) 0.1347
aAdjusted for study arm and the following socio-demographic variables: Year of birth, ethnicity, degree of urbanisation in area of habitat, completed educational
level, parents’ educational level, and primary care contacts within the previous year
b for an unvaccinated woman
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to be HPV vaccinated than attenders are, inequity in
health will be aggravated.
Conclusions
Our study suggests that HPV vaccinated as well as unvac-
cinated women have inflated perceptions of cervical cancer
risk. Moreover, vaccinated women are much more inclined
to participate in screening than unvaccinated women. This
is concerning, since those who would benefit the most from
screening might not participate, while healthcare resources
are spent on those who benefits least. The implications for
practice are mainly pertaining to future information inter-
ventions directed at women invited for cervical screening.
Both groups of women should be provided with clear and
balanced information about their personal cervical
cancer risk (i.e. according to HPV vaccination status) and
the benefits and harms of screening based on best avail-
able evidence, so that they have the best possible prerequi-
sites to make an informed choice.
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of screening intention. (DOCX 14 kb)
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